European Society of Cardiology Congress - Stroke Spotlight

Robert Giugliano, MD, breaks down his prespecified subanalysis of the VESALIUS-CV trial, evaluating evolocumab’s effect on cardiovascular mortality.

Jose Nicolau, MD, PhD, discusses the results of his subanalysis of the VESALIUS-CV trial, examining secondary rather than first MACE.

Catch up on any stroke-related news you may have missed during 4 action-packed days of presentations and trial readouts at ESC 2026.

Charalambos Antoniades, MD, PhD, discusses the recent trial investigating an AI-powered stroke and atrial fibrillation predictor.

The China Rural Hypertension Control Program found a non-physician-led intensive blood pressure intervention reduced dementia risk by 15% over 7 years.

EPIDAURUS stopped early after potent P2Y12 inhibitors plus a DOAC raised bleeding without reducing ischemic events in patients with AF and MI.

ACASA-TAVI found NOAC monotherapy cut subclinical leaflet thrombosis nearly in half versus aspirin after TAVI, meeting safety noninferiority.

Ashkan Shoamanesh, MD, discusses individualizing stroke prevention after ENRICH-AF, from LAAO to factor XI inhibitors to the ASPIRE trial.

Ashkan Shoamanesh, MD, explains ENRICH-AF's mixed stroke and bleeding results, and a dosing signal that may point to a safer approach.

CMR GUIDE found ICD implantation did not significantly reduce sudden cardiac death or dangerous arrhythmia versus a loop recorder in LVEF 36-50%.

A longitudinal survey found PSVT disrupts patients' daily activities, sleep, and emotions between episodes.

POET-II found tailored antibiotics cut treatment duration by a third in left-sided infective endocarditis without compromising safety, per ESC 2026 data.

PREMIUM found prasugrel monotherapy before primary PCI raised ischemic risk vs DAPT in STEMI despite less major bleeding, per ESC Congress 2026 data.

Philippe Gabriel Steg, MD, discusses the full results of the terminated trial, reflecting on their impact on the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials.

Milvexian added to standard antiplatelet therapy did not lower MACE or increase intracranial/fatal bleeding versus placebo after ACS.

The ENRICH-AF trial found edoxaban did not significantly reduce stroke or systemic embolism but increased major bleeding in patients with AF and prior intracranial hemorrhage.

A new study has indicated the correlation between EHT and atrial myopathy, which in turn contributes to potential ischemic stroke incidence.

Both apixaban and rivaroxaban resulted in improved risk of stroke, systemic embolism, major bleeding, and cardiovascular death compared to no anticoagulation.